RFG Advisory’s Tarsus Pharmaceuticals TARS Stock Holding History

RFG Advisory’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,941	Closed	-$888K	–	1036
2025 Q3	$888K	Buy	+14,941	New	+$736K	0.02%	520

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RFG Advisory's TARS Position: Q4 2025 in Review

RFG Advisory sold out of Tarsus Pharmaceuticals (TARS) in Q4 2025, closing a stake of 14,941 shares — an estimated $888K sold.

RFG Advisory first reported a position in TARS in Q3 2025 and held it in 1 quarter. The position peaked at $888K in Q3 2025. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

RFG Advisory reported no remaining Tarsus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
RFG Advisory sold 14,941 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $888K.
RFG Advisory first reported a position in Tarsus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
RFG Advisory's Tarsus Pharmaceuticals position peaked at $888K in Q3 2025.
246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on RFG Advisory's 13F filing for Q4 2025, filed 3 Feb 2026.